157 related articles for article (PubMed ID: 38538421)
1. Re: Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma.
Tilgener C; Bedke J
Eur Urol; 2024 Jun; 85(6):591-592. PubMed ID: 38538421
[No Abstract] [Full Text] [Related]
2. Erdafitinib (Balversa) for urothelial carcinoma.
Med Lett Drugs Ther; 2024 May; 66(1702):e83-e84. PubMed ID: 38696316
[No Abstract] [Full Text] [Related]
3. [High response rates for erdafitinib in patients with FGFR-mutated urothelial carcinoma following failure of platinum-based chemotherapy].
Grülllich C
Urologe A; 2020 Apr; 59(4):478-479. PubMed ID: 32103289
[No Abstract] [Full Text] [Related]
4. Erdafitinib: First Global Approval.
Markham A
Drugs; 2019 Jun; 79(9):1017-1021. PubMed ID: 31161538
[TBL] [Abstract][Full Text] [Related]
5. Fibroblast growth factor receptors across urothelial carcinoma landscape.
Ertl IE; Shariat SF; Mostafaei H; Ilijazi D; Loriot Y
Curr Opin Urol; 2020 Jul; 30(4):557-565. PubMed ID: 32452999
[TBL] [Abstract][Full Text] [Related]
6. Erdafitinib for advanced urothelial carcinoma.
Burki TK
Lancet Oncol; 2019 Sep; 20(9):e469. PubMed ID: 31378458
[No Abstract] [Full Text] [Related]
7. Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study.
Siefker-Radtke AO; Necchi A; Park SH; García-Donas J; Huddart RA; Burgess EF; Fleming MT; Rezazadeh Kalebasty A; Mellado B; Varlamov S; Joshi M; Duran I; Tagawa ST; Zakharia Y; Akapame S; Santiago-Walker AE; Monga M; O'Hagan A; Loriot Y;
Lancet Oncol; 2022 Feb; 23(2):248-258. PubMed ID: 35030333
[TBL] [Abstract][Full Text] [Related]
8. Erdafitinib for locally advanced or metastatic urothelial carcinoma.
Siefker-Radtke AO; Loriot Y
Am J Health Syst Pharm; 2022 May; 79(11):824-825. PubMed ID: 35147178
[No Abstract] [Full Text] [Related]
9. [First line therapy for locally advanced or metastatic urothelial cancer : A randomized double blind phase III multicenter study on adjuvant nivolumab therapy versus placebo in patients with invasive high-risk urothelial cancer (CheckMate 274)-AB 58/17 of the AUO].
Rexer H; Ohlmann CH; Gschwend J;
Urologe A; 2017 Oct; 56(10):1331-1332. PubMed ID: 28779222
[No Abstract] [Full Text] [Related]
10. Financial toxicity from newly approved second-/third-line agents in metastatic urothelial carcinoma.
Benjamin DJ; Lythgoe MP; Rezazadeh A
BJU Int; 2023 Jun; 131(6):691-693. PubMed ID: 36877951
[No Abstract] [Full Text] [Related]
11. Identifying fibroblast growth factor receptor genetic alterations using RNA-based assays in patients with metastatic or locally advanced, surgically unresectable, urothelial carcinoma who may benefit from erdafitinib treatment.
Wang S; Burgess M; Major C; English A; Sweeney M; Hartmann A
J Pathol Clin Res; 2020 Jul; 6(3):207-214. PubMed ID: 32304281
[TBL] [Abstract][Full Text] [Related]
12. ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma.
Powles T; Bellmunt J; Comperat E; De Santis M; Huddart R; Loriot Y; Necchi A; Valderrama BP; Ravaud A; Shariat SF; Szabados B; van der Heijden MS; Gillessen S;
Ann Oncol; 2024 Jun; 35(6):485-490. PubMed ID: 38490358
[No Abstract] [Full Text] [Related]
13. Erdafitinib as a Novel and Advanced Treatment Strategy of Metastatic Urothelial Carcinoma.
Bansal P; Dwivedi DK; Hatwal D; Sharma P; Gupta V; Goyal S; Maithani M
Anticancer Agents Med Chem; 2021; 21(18):2478-2486. PubMed ID: 33475078
[TBL] [Abstract][Full Text] [Related]
14. Overview of the clinical use of erdafitinib as a treatment option for the metastatic urothelial carcinoma: where do we stand.
D'Angelo A; Bagby S; Galli IC; Bortoletti C; Roviello G
Expert Rev Clin Pharmacol; 2020 Oct; 13(10):1139-1146. PubMed ID: 32935605
[TBL] [Abstract][Full Text] [Related]
15. Erdafitinib exerts the anticancer effect on urothelial carcinoma
Jin YY; Tong SQ; Tong M
Pharmazie; 2020 May; 75(5):195-197. PubMed ID: 32393427
[TBL] [Abstract][Full Text] [Related]
16. Bempegaldesleukin/Nivolumab and Challenges in First-line Treatment of Metastatic Urothelial Carcinoma.
Miron B; Geynisman DM
Eur Urol; 2022 Oct; 82(4):374-376. PubMed ID: 35752503
[No Abstract] [Full Text] [Related]
17. Editorial Comment to Real-world sequential treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in Japan.
Kondo T
Int J Urol; 2024 May; 31(5):560-561. PubMed ID: 38424666
[No Abstract] [Full Text] [Related]
18. Editorial Comment on Real-world sequential treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in Japan.
Ishihara H; Takagi T
Int J Urol; 2024 May; 31(5):559-560. PubMed ID: 38366784
[No Abstract] [Full Text] [Related]
19. Erdafitinib's Road to Approval and Use in Urothelial Carcinoma.
Hanna K
Oncology (Williston Park); 2023 Jun; 37(6):260-261. PubMed ID: 37343205
[No Abstract] [Full Text] [Related]
20. Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial.
Siefker-Radtke AO; Matsubara N; Park SH; Huddart RA; Burgess EF; Özgüroğlu M; Valderrama BP; Laguerre B; Basso U; Triantos S; Akapame S; Kean Y; Deprince K; Mukhopadhyay S; Loriot Y;
Ann Oncol; 2024 Jan; 35(1):107-117. PubMed ID: 37871702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
